secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001193125-23-202314
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude posts Q2 net loss $30.4M; cash $255M funds operations into 2026
-----------------------------------------------------------------------

- Net loss of $30.4M ($0.54/share) vs $27.4M ($0.58/share) in Q2 2022.
- R&D expense rose to $25.0M from $21.3M YoY; G&A fell to $7.4M from $8.2M.
- Cash, equivalents and marketable securities $255.0M; completed public offering raising $113M gross.
- Pipeline milestones: CDK9 (PRT2527) confirmation dose target Q1 2024; SMARCA2 degrader IND early 2024.
- Management expects cash runway into 2026; four lead programs on track for data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312523202314/0001193125-23-202314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312523202314/d870924d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-202314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer